Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
- 31 March 2009
- journal article
- Published by Elsevier BV in Leukemia Research
- Vol. 33 (3), 465-473
- https://doi.org/10.1016/j.leukres.2008.08.025
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis inductionBlood, 2002
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent ApoptosisBlood Cells, Molecules, and Diseases, 2000
- Signaling events involved in anti-CD20-induced apoptosis of malignant human B cellsCancer Immunology, Immunotherapy, 2000
- Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal AntibodyJapanese Journal of Cancer Research, 1998
- Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal AntibodiesBlood, 1998
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994